Sulbactam · Unasyn, CP-458992

What is Sulbactam?

Sulbactam is a semi-synthetic beta-lactamase inhibitor that irreversibly binds to bacterial beta-lactamase, blocking its activity and preventing degradation of beta-lactam antibiotics. Combined with ampicillin or other beta-lactam agents, it treats infections caused by beta-lactamase-producing bacteria in skin, intra-abdominal, and gynecological sites. It is also studied in non-tuberculous mycobacterial infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Unasyn, CP-458992, NSC-759886, SUL-DUR

Drug type

Small molecule

Targets

beta-lactamase

Mechanism

Inhibitor of beta-lactamase

Therapy area

Infectious disease

Developer

Roerig

In trials of

INVA

FDA status

Approved as Unasyn, NDA050608 · FDA label

UNII

S4TF6I2330

✅ FDA-approved uses

• Skin and Skin Structure Infections
• Intra-Abdominal Infections
• Gynecological Infections

From the indications section of the FDA label (version of Jul 10, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) Infections

Sources

• FDA label Unasyn (2026-07-10), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT06801223
• ClinicalTrials.gov NCT06801223
• ClinicalTrials.gov NCT07485010

Updated Oct 3, 2026.